Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tuparstobart · INCAGN-02385, AGEN-2385

Monoclonal antibody · Antagonist of lymphocyte-activation gene 3 protein (LAG3) · developed by Incyte

Phase 2 Most advanced trial (none active)
INCY Developer

What is Tuparstobart?

Tuparstobart is an Fc-engineered IgG1-kappa monoclonal antibody that binds the co-inhibitory receptor LAG-3 on tumor-infiltrating lymphocytes. It blocks LAG-3 interaction with MHC class II molecules, relieving suppression of T-cell activity. It is being studied in head and neck cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
INCAGN-02385, AGEN-2385
Drug type
Monoclonal antibody
Targets
lymphocyte-activation gene 3 protein (LAG3), major histocompatibility complex class II (MHC II) (binding partner it blocks)
Mechanism
Antagonist of lymphocyte-activation gene 3 protein (LAG3)
Pathways
LAG-3-MHC II interaction blockade, T-cell activation, cytotoxic T-lymphocyte response
Therapy area
Oncology
Developer
Incyte Corporation (INCY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
Z0A08C63DF

Conditions studied

Head and Neck Cancer

Other drugs acting on LAG3

More from Incyte

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the INCY page.

Follow INCY, the company behind Tuparstobart

See INCY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

INCY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.